Scientists at GT Apeiron Therapeutics and Shanghai Apeiron Biotechnology Co. Ltd. have divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
NKG2A is an inhibitory immune checkpoint receptor expressed on cytotoxic T cells and natural killer (NK) cells. Its upregulation in the tumor microenvironment (TME) contributes to the functional exhaustion of T cells, enabling tumor cells to evade immune surveillance. Therapeutic targeting of NKG2A represents a promising strategy to restore T-cell activity and enhance antitumor immunity.
Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of treated patients suffer progression or recurrence. In an effort to find more effective treatments for refractory disease, researchers at the Université de Sherbrooke and its hospital research center have engineered an oncolytic vesicular stomatitis virus encoding granulocyte-macrophage colony-stimulating factor (VSVd51-GM-CSF).
Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer.
The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the Topo1 enzyme and increased drug efflux mediated by ATP-binding cassette (ABC) transporters, particularly ABCG2 (BCRP).
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant cancers, with limited therapeutic options and poor survival rates. The development of targeted therapies that disrupt multiple signaling pathways simultaneously could offer new opportunities to improve outcomes in this disease.
Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 (Ac-225) to target a non-prostate-specific member antigen (PSMA) protein that is frequently overexpressed in several tumor types, including prostate cancer.
RSS
